Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter

被引:40
作者
Ding, Jia [1 ]
Zhou, Xiao-Tian [2 ]
Zou, Hao-Yu [2 ]
Wu, Jian [2 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Gastroenterol, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, Dept Med Microbiol,Key Lab Mol Virol, 138 Yixue Yuan Rd,POB 228, Shanghai 200032, Peoples R China
关键词
HEPATOCELLULAR-CARCINOMA; SUPEROXIDE-DISMUTASE; ADJUVANT SORAFENIB; GENE DELIVERY; CANCER; CHEMORESISTANCE; ACTIVATION; COMPONENTS; RESISTANCE; APOPTOSIS;
D O I
10.1038/labinvest.2017.34
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The poor response to drug therapy often seen in hepatocellular carcinoma requires insight into the molecular interplay responsible for intrinsic or acquired drug resistance. We previously demonstrated that the CD133(-)/EpCAM-subpopulation of the Huh-7 hepatoma cell line features aberrant activation of the hedgehog signaling (Hh) pathway and chemoresistance. The prevailing hypothesis of the present study is that hedgehog signaling may govern expression of ATP-binding cassette (ABC) transporters, which are responsible for drug resistance in the CD133(-)/EpCAM-subpopulation. Our aim is to reveal the molecular interplay in the mediation of drug resistance with a newly established Huh-7 subpopulation featuring high Hh signaling activity and drug resistance. In this study, chemoresistance was determined in a newly established Huh-7-DN subpopulation featuring the CD133(-)/EpCAM-surface marker profile, aberrant expression of Hh pathway, and epithelial-mesenchymal transition (EMT). Expression of ABC transporter proteins (ABCB1, ABCC1, and ABCG2) and Hh transcription factor Gli-1/2 was evaluated with and without Hh signaling antagonists LDE225 or itraconazole. We found that hedgehog signaling activity as determined by transfection with a Gli-Lux reporter cassette and gene expression levels tended to increase from Huh-7 CD133(+)/EpCAM+ to CD133(-)/EpCAM(-), and the highest levels were found in Huh-7-DN cells. The Huh-7-DN subpopulation exhibited characteristics of EMT as evidenced by increased expression of vimentin and loss of E-cadherin. Sorafenib significantly inhibited the viability of all subpopulations except the Huh-7-DN subpopulation. Compared with other sorafenib-sensitive subpopulations, the Huh-7-DN subpopulation showed enhanced expression of Hh transcription factor Gli-2 and ABCC1 transporter protein. Silencing Gli-2 by lentivirus harboring shRNA against Gli-2 or LDE225 significantly suppressed expression of Gli-2 and ABCC1 genes in Huh-7-DN subpopulation. In conclusion, aberrant hedgehog signaling activation is linked to poor differentiation, epithelialmesenchymal transition, and chemoresistance in the Huh-7-DN subpopulation. Hedgehog signaling transcription factor Gli-2 appears to be the primary regulator for drug sensitivity of hepatoma through the ABCC1 transporter.
引用
收藏
页码:819 / 832
页数:14
相关论文
共 35 条
  • [1] Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
    Blotta, Simona
    Jakubikova, Jana
    Calimeri, Teresa
    Roccaro, Aldo M.
    Amodio, Nicola
    Azab, Abdel Kareem
    Foresta, Umberto
    Mitsiades, Constantine S.
    Rossi, Marco
    Todoerti, Katia
    Molica, Stefano
    Morabito, Fortunato
    Neri, Antonino
    Tagliaferri, Piersandro
    Tassone, Pierfrancesco
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    [J]. BLOOD, 2012, 120 (25) : 5002 - 5013
  • [2] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    Bruix, Jordi
    Takayama, Tadatoshi
    Mazzaferro, Vincenzo
    Chau, Gar-Yang
    Yang, Jiamei
    Kudo, Masatoshi
    Cai, Jianqiang
    Poon, Ronnie T.
    Han, Kwang-Hyub
    Tak, Won Young
    Lee, Han Chu
    Song, Tianqiang
    Roayaie, Sasan
    Bolondi, Luigi
    Lee, Kwan Sik
    Makuuchi, Masatoshi
    Souza, Fabricio
    Le Berre, Marie-Aude
    Meinhardt, Gerold
    Llovet, Josep M.
    [J]. LANCET ONCOLOGY, 2015, 16 (13) : 1344 - 1354
  • [3] Sonidegib: First Global Approval
    Burness, Celeste B.
    [J]. DRUGS, 2015, 75 (13) : 1559 - 1566
  • [4] Expression of Sonic Hedgehog Signaling Components in Hepatocellular Carcinoma and Cyclopamine-induced Apoptosis Through Bcl-2 Downregulation In Vitro
    Chen, Xi-lin
    Cheng, Quan-yong
    She, Miao-rong
    Wang, Qian
    Huang, Xiao-hui
    Cao, Liang-qi
    Fu, Xin-hui
    Chen, Jing-song
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2010, 41 (05) : 315 - 323
  • [5] Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations
    Chen, Xiaoli
    Lingala, Shilpa
    Khoobyari, Shiva
    Nolta, Jan
    Zern, Mark A.
    Wu, Jian
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (04) : 838 - 845
  • [6] Hedgehog Signaling Regulates Drug Sensitivity by Targeting ABC Transporters ABCB1 and ABCG2 in Epithelial Ovarian Cancer
    Chen, Yi
    Bieber, Marcia M.
    Teng, Nelson N. H.
    [J]. MOLECULAR CARCINOGENESIS, 2014, 53 (08) : 625 - 634
  • [7] Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells
    Fan, Y-H
    Ding, J.
    Nguyen, S.
    Liu, X-J
    Xu, G.
    Zhou, H-Y
    Duan, N-N
    Yang, S-M
    Zern, M. A.
    Wu, J.
    [J]. ONCOGENE, 2016, 35 (01) : 116 - 124
  • [8] Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms
    Fendrich, Volker
    Wiese, Dominik
    Waldmann, Jens
    Lauth, Matthias
    Heverhagen, Anna E.
    Rehm, Johannes
    Bartsch, Detlef K.
    [J]. ANNALS OF SURGERY, 2011, 254 (05) : 818 - 823
  • [9] Systemic therapies for hepatocellular carcinoma
    Ge, Shaohua
    Huang, Dingzhi
    [J]. DRUG DISCOVERIES AND THERAPEUTICS, 2015, 9 (05) : 352 - 362
  • [10] Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
    Gonnissen, Annelies
    Isebaert, Sofie
    Haustermans, Karin
    [J]. ONCOTARGET, 2015, 6 (16) : 13899 - 13913